Compare Recursion Pharmaceuticals Inc (RXRX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3442.3× 22nd Century Group Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and 22nd Century Group Inc for 32 Days on average.
| RXRX | XXII | |
|---|---|---|
Market Cap | $2.14B | $621.67K |
Volume | 30,789,535 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $483.00 |
52-Week Low | $2.84 | $0.80 |
Typical Hold Time | 23 Days | 32 Days |
Enterprise Value | $1.66B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
